home > news > detailed info

PCI Pharma Services Announces Organization Updates

PCI Pharma Services

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.

The senior positions include newly created and expanded roles in Strategic Marketing, Program Management, Clinical Services and Global Clinical Quality.

Commenting on the changes, PCI Chief Executive Officer Salim Haffar said: “The strategic direction PCI is taking will help us and our clients prepare for the future. We are investing in global infrastructure, innovation, and our leadership to ensure enhanced focus on delivering the best customer experience and solidifying our well-recognized position within the industry. I’m inspired by the strength of our internal management team, and our ability to elevate and leverage their talent to launch these new functions and initiatives.”

• To support the continued growth and strength of PCI’s Clinical Services business, Tim Roberts has been promoted to the position of Vice President, Global Sales, Clinical Services. With a 22-year career in clinical packaging, Tim has been successfully leading and building PCI’s US Clinical Sales Team for the last four years, and before this led its UK Clinical Operations. He has made a significant and positive impact on team members, Clinical business results and most importantly PCI’s client base. Prior to joining PCI, Tim delivered strong results at Catalent and Aptuit in sales, program management and operations leadership roles.

• In a key role in Quality, Tris Evans has been promoted to the position of Vice President, Global Quality, Clinical Services, and will lead the Clinical Quality Directors and teams at PCI’s Rockford, San Diego, Bridgend, Dublin and Hay sites. In Tris’ 11 years with PCI, he has been very successful in leading and building a well-recognized Global Clinical Quality team, ensuring harmonization of Clinical Quality standards globally, supporting key activities and business drivers and delighting PCI’s customers. Previously, Tris worked at Norgine and Penn Pharma in roles of increasing responsibility in Quality.

• Driving alignment and consistency for PCI’s Commercial clients, Justin Schroeder has been promoted to the newly created role of Vice President, Global Program Management; a position designed to secure PCI’s reputation of providing the best customer experience in our industry through the program management team. Justin is well placed for this role; during his 19-year history with PCI, he has served in numerous executive, client-facing roles including packaging design, program management, and marketing. During his tenure, he has built world-class teams which have differentiated PCI as a technology leader and driven year over year revenue growth.

• As PCI prepares to increase its presence worldwide, Sue Ritchie has been promoted to the role of Senior Director, Global Marketing. The purpose and scope of this new role is to expand PCI’s brand awareness and impact across the globe, leveraging external and internal resources to continue to drive innovation and recognition. Sue has most recently served in a Business Development role with PCI, increasing sales and relationships for its Manufacturing business. Prior to PCI, Sue held numerous senior level marketing positions at Delavau, Johnson and Johnson, Pfizer and GE Healthcare. She has a strong track record of marketing intelligence, strategy and execution and will bring that knowledge to PCI in her new role.

For further information about PCI’s expertise, please visit here.

About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.

For more information, please visit or follow us on Twitter at @PCI_Social.

Tom Gosschalk / Carrie Lowe at BECG
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement